Teva Canada has recalled one lot of Teva-Pregabalin 150 mg capsules sold across the country after routine testing found some capsules may be contaminated with sertraline, an antidepressant, Health Canada said in a public advisory.
The affected product is Teva-Pregabalin 150 mg capsules, drug identification number (DIN) 02361205, from lot 100070495100068913. The lot expires July 31, 2027, and the capsules were first sold in September 2025, according to the advisory.
Health Canada said the risk applies mainly to people who are allergic or hypersensitive to sertraline. For them, taking a contaminated capsule could cause side effects or a serious allergic reaction, including anaphylaxis.
Pregabalin is a prescription medication used to treat nerve pain and certain other conditions. The recall covers only the one lot listed. Other strengths and other lots of Teva-Pregabalin are not part of it.
The advisory lists the signs of a severe allergic reaction as difficulty breathing or wheezing, swelling of the face or throat, loss of consciousness or severe dizziness, and a rash or hives. Health Canada said anyone who has these symptoms should call 911 or go to the nearest emergency department.
The agency said people who have the recalled lot should not stop taking pregabalin abruptly without first talking to their pharmacist or doctor, because stopping suddenly can cause withdrawal symptoms. It said they should return the product to their pharmacy for replacement and safe disposal.
To check a bottle, compare the lot number and DIN on the label with the numbers above. The lot number is usually printed on the bottle or the outer carton, near the expiry date. If you are not sure, a pharmacist can look it up.
Teva Canada can be reached at 1-800-268-4129 with questions about the recall. Consumers can also contact Health Canada at 613-957-2991 or 1-866-225-0709.
The recall was published in August 2026 and was also listed in Health Canada’s September edition of Health Product InfoWatch, a monthly publication for health professionals that summarizes safety information on drugs, devices and natural health products. Product was distributed nationwide.
Contamination of this kind, where a small number of capsules contain a different drug, is usually found during manufacturers’ routine quality testing. Health Canada has not reported any illnesses linked to this lot in the advisory.
This article is based on official guidance from Health Canada and is provided for general public information. It’s not a substitute for medical advice, if you have questions about how this applies to you, talk to your doctor or pharmacist.
If you find reporting like this useful, consider supporting Canada News Media, an independent Canadian newsroom with no corporate parent.
Sources: Health Canada, Teva-Pregabalin 150 mg recall advisory; Health Canada, Health Product InfoWatch, September 2026.
